Last reviewed · How we verify
Anxiety and Depression in Epilepsy: A Treatment Study
As a potential solution to address high rates of depression and anxiety seen in epilepsy patients and poor mental health care access, this randomized trial aims to study treatment for anxiety and depression in epilepsy taking place directly within the epilepsy clinic vs. psychiatry referral (typical care). Patients that meet eligibility criteria, including significant symptoms of depression and/or anxiety, will be randomized to the either the intervention group or the control group. Patients that do not meet eligibility requirement or decline the study intervention will have the option of participating in the survey arm of the study. The intervention will consist of an initial prescription for an FDA-approved medication to treat depression/anxiety and telephone-based chronic care management plan for repeated symptom measurement and side effect surveillance. The control group will receive usual care, which is a referral order to psychiatry placed by their treating neurologist. Participants in the survey arm of the study will complete a one time survey.
Details
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 69 |
| Start date | Mon May 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Sep 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Anxiety
- Depression
- Epilepsy
Interventions
- Escitalopram 10mg
- Referral to Psychiatry
- Survey only
Countries
United States